In the news release, Heska Fourth Quarter and Full Year 2022
Financial Results and Earnings Call Scheduled for February 28, 2023, issued 08-Feb-2023 by Heska Corporation over PR
Newswire, the conference call United
States phone number was missing a digit, the correct phone
number is 1-877-451-6152 rather than 1-877-41-6152 as incorrectly
transmitted by PR Newswire. The complete, corrected release
follows:
Heska Fourth Quarter and Full Year 2022 Financial Results and
Earnings Call Scheduled for February 28, 2023
LOVELAND, Colo., Feb. 8, 2023
/PRNewswire/ -- Heska Corporation (NASDAQ: HSKA; "Heska" or
the "Company"), a leading global provider of advanced veterinary
diagnostic and specialty solutions, will report its fourth quarter
and full year 2022 financial performance in a press release before
the market opens on Tuesday, February 28,
2023. The Company will also host an earnings call at
9 a.m. MT / 11
a.m. ET to discuss the results.
To access the conference call:
From within the United
States, please dial 1-877-451-6152
From outside of the United States,
please dial 1-201-389-0879
Reference Conference ID: 13736218
The earnings call will be webcast live from the Company's
investor relations website at: Heska Fourth Quarter and Full Year
Earnings Call Webcast.
A telephonic replay will be available at 2 p.m. ET on February
28th through 11:59 p.m.
ET on March 14, 2023 and the
webcast will be archived on the Company's website for 90 days.
To access the replay by telephone:
From within the United
States, please dial 1-800-512-2921
From outside the United States,
please dial 1-412-317-6671
Reference Replay Pin Number: 13736218
About Heska
Heska Corporation (NASDAQ: HSKA) sells, manufactures, markets,
and supports diagnostic and specialty products and solutions for
veterinary practitioners. Heska's portfolio includes point-of-care
diagnostic laboratory instruments and consumables including rapid
assay diagnostic products; digital cytology services; point-of-care
digital imaging diagnostic products; local and cloud-based data
services; practice information management software ("PIMS") and
related software and support; reference laboratory testing; allergy
testing and immunotherapy; heartworm preventive products; and
vaccines. Heska's primary focus is supporting companion animal
veterinarians in providing care to their patients.
Heska's business is composed of two operating and reportable
segments: North America and
International. North America
consists of the United States,
Canada and Mexico. International consists of geographies
outside of North America,
primarily in Germany, Italy, Spain,
France, Switzerland, Australia and Malaysia. The Company's strategic focus on
point-of-care diagnostic laboratory and imaging products is
included in both segments. The North
America segment also includes the contract manufacturing of
vaccines and pharmaceutical products and a small veterinary
laboratory, and the International segment includes PIMS business
and veterinary laboratories. For more information, please visit
www.heska.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/heska-fourth-quarter-and-full-year-2022-financial-results-and-earnings-call-scheduled-for-february-28-2023-301741596.html
SOURCE Heska Corporation